Positive News SentimentPositive NewsNASDAQ:CPIX Cumberland Pharmaceuticals (CPIX) Stock Price, News & Analysis $3.49 +0.01 (+0.29%) Closing price 04:00 PM EasternExtended Trading$3.50 +0.01 (+0.43%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cumberland Pharmaceuticals Stock (NASDAQ:CPIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CPIX alerts:Sign Up Key Stats Today's Range$3.25▼$3.5250-Day Range$2.55▼$5.8952-Week Range$1.04▼$7.25Volume42,899 shsAverage Volume84,901 shsMarket Capitalization$52.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee. Read More Cumberland Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreCPIX MarketRank™: Cumberland Pharmaceuticals scored higher than 24% of companies evaluated by MarketBeat, and ranked 845th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Cumberland Pharmaceuticals. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cumberland Pharmaceuticals is 38.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.89.Price to Earnings Ratio vs. SectorThe P/E ratio of Cumberland Pharmaceuticals is 38.67, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.22.Price to Book Value per Share RatioCumberland Pharmaceuticals has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cumberland Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.10% of the float of Cumberland Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCumberland Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cumberland Pharmaceuticals has recently decreased by 87.52%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCumberland Pharmaceuticals does not currently pay a dividend.Dividend GrowthCumberland Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.10% of the float of Cumberland Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCumberland Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cumberland Pharmaceuticals has recently decreased by 87.52%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment1.89 News SentimentCumberland Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cumberland Pharmaceuticals this week, compared to 9 articles on an average week.Search InterestOnly 1 people have searched for CPIX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cumberland Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders44.85% of the stock of Cumberland Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.51% of the stock of Cumberland Pharmaceuticals is held by institutions.Read more about Cumberland Pharmaceuticals' insider trading history. Receive CPIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cumberland Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CPIX Stock News HeadlinesCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATEJuly 29 at 4:18 PM | prnewswire.comAt least 8 cats dead in Cumberland Co. house fire, local rescue searching for moreJuly 18, 2025 | msn.comYour Pre-IPO Access Approved ✅This means you can receive new details about this brand new Pre-IPO space stock opportunity... ... and how to buy Pre-IPO shares for less than $4. My estimates suggest shares could jump 457% after the IPO. They’re now completing a FINAL Pre-IPO financing.July 29 at 2:00 AM | Wyatt Investment Research (Ad)Have what it takes to be the next sheriff? Cumberland County opens application processJuly 18, 2025 | msn.comCumberland Valley nabs 5 selections on PVCA All-State teamJuly 18, 2025 | msn.comWhat $400,000 or less gets you in Cumberland County, July 7 to 13July 18, 2025 | nj.comNCumberland County borough issues boil water advisoryJuly 18, 2025 | msn.com3 injured in major crash at Paluxy Dr., Cumberland Rd. in TylerJuly 18, 2025 | msn.comSee More Headlines CPIX Stock Analysis - Frequently Asked Questions How have CPIX shares performed this year? Cumberland Pharmaceuticals' stock was trading at $2.37 at the beginning of the year. Since then, CPIX shares have increased by 47.3% and is now trading at $3.49. How were Cumberland Pharmaceuticals' earnings last quarter? Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced its quarterly earnings data on Tuesday, May, 6th. The specialty pharmaceutical company reported $0.15 earnings per share for the quarter. Cumberland Pharmaceuticals had a positive trailing twelve-month return on equity of 6.92% and a negative net margin of 7.98%. Read the conference call transcript. How do I buy shares of Cumberland Pharmaceuticals? Shares of CPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cumberland Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cumberland Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Exxon Mobil (XOM), Netflix (NFLX) and Intel (INTC). Company Calendar Last Earnings5/06/2025Today7/29/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CPIX CIK1087294 Webwww.cumberlandpharma.com Phone(615) 255-0068Fax615-255-0094Employees80Year Founded1999Profitability EPS (Trailing Twelve Months)($0.25) Trailing P/E Ratio38.67 Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.48 million Net Margins-7.98% Pretax Margin-8.08% Return on Equity6.92% Return on Assets2.33% Debt Debt-to-Equity Ratio0.18 Current Ratio1.25 Quick Ratio1.09 Sales & Book Value Annual Sales$37.87 million Price / Sales1.38 Cash Flow$0.26 per share Price / Cash Flow13.53 Book Value$1.61 per share Price / Book2.17Miscellaneous Outstanding Shares14,960,000Free Float8,251,000Market Cap$52.21 million OptionableOptionable Beta-0.39 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CPIX) was last updated on 7/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cumberland Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cumberland Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.